Transforming the way scientists are treating the body’s response to diseases.

The goal of our toll-like receptor (TLR) agonist platform and clinical development program is to tap into the natural function of the immune system from within the tumor environment with our lead TLR9 agonist, tilsotolimod, essentially giving the system a boost to affect the treated tumor as well as initiating a reaction from outside the tumor to provide for systemic treatment.

We have demonstrated pre-clinically and more recently clinically, that by combining Ipilimumab (an anti-CTLA4 antibody) , a currently approved treatment for metastatic melanoma, with our intratumoral tilsotolimod (IMO-2125), we can enable these therapies to have deeper and longer-lasting responses in patients who are refractory to anti-PD1 therapy.

We are currently enrolling our Phase 2 multi-center clinical trial of tilsotolimod in combination with Ipilimumab in PD-1 refractory metastatic melanoma patients.   We also are enrolling an arm in this trial to test the combination of tilsotolimod with Pemrolizumab and have recently initiated a multi-center clinical trial of IMO-2125 as a monotherapy in melanoma and numerous other solid tumors and plan to open additional trials to explore further combination regimens in other solid tumor types.

Based on the data we have generated to date, we are also in parallel enrolling a global Phase 3 clinical trial in anti-PD-1 refractory patients measuring the combination of tilsotolimid and ipilimumab versus ipilimubab treatment along.  This trial will be enrolling approximately 300 patients across 80 global trial sites.

For more information on these studies, go to the U.S. FDA Clinical Trial Registry Website ,contact Idera at clinicaltrials@iderapharma.com or visit Idera’s Clinical Trials Website.

  • Our Approach

    Learn more about our unwavering dedication to helping patients defeat cancer.